What Does the Published Research Say About AOD-9604?

Research Context

The packet includes: (a) limited direct human data indicating favorable safety/tolerability for AOD-9604 in a phase II clinical setting and FDA PCAC materials outlining clinical/regulatory context [crossref:10.2165/00128413-200313770-00018; fda:pcac-aod-9604-183891; fda:pcac-aod-9604-183584]; (b) review literature on therapeutic peptides and obesity pharmacotherapy that provides field context but not AOD-9604–specific clinical outcomes [pubmed:41490200; pubmed:16931496; pubmed:17971763; pubmed:22435392; pubmed:16625817; pubmed:15134286]; and (c) preclinical studies (animal/in vitro) plus analytical/anti-doping detection literature for AOD-9604 and related growth-hormone fragments [pubmed:11673763; pubmed:11713213; pubmed:11146367; pubmed:25208511; pubmed:24124033; pubmed:26213263].

Key Takeaway

In this packet, direct human evidence for AOD-9604 is limited to a phase II safety/tolerability signal; the provided citations do not establish human efficacy outcomes.

Direct Answer

• A phase II clinical study reported favorable safety and tolerability for AOD-9604; conclusions should remain limited to the specific population and endpoints studied (safety/tolerability-focused) [crossref:10.2165/00128413-200313770-00018; fda:pcac-aod-9604-183891].
• Reviews frame the broader peptide and obesity-therapy landscape but are not substitutes for primary human outcome evidence and are not specific proof of AOD-9604 clinical benefit [pubmed:41490200; pubmed:16931496; pubmed:17971763; pubmed:22435392; pubmed:16625817; pubmed:15134286].
• Preclinical mouse and in vitro studies report metabolic/lipolytic or characterization findings; these do not establish human outcomes [pubmed:11673763; pubmed:11713213; pubmed:11146367; pubmed:25208511]. In some rodent work, related GH fragments were studied that may not be identical to AOD-9604.
• Analytical studies address detection and assay interference; they inform testing context, not clinical efficacy or safety [pubmed:24124033; pubmed:26213263; pubmed:25208511].

Direct human evidence

• A phase II clinical trial in an obesity-related context reported a favorable safety/tolerability signal for AOD-9604; the evaluated endpoints focused on safety/tolerability rather than efficacy [crossref:10.2165/00128413-200313770-00018; fda:pcac-aod-9604-183891].
• Guardrail: Do not infer efficacy or generalized safety beyond the specific population and endpoints evaluated in the cited human study and FDA PCAC review materials [crossref:10.2165/00128413-200313770-00018; fda:pcac-aod-9604-183891; fda:pcac-aod-9604-183584].

Review literature (field context; not proof of outcomes)

• Reviews cover therapeutic peptides (including an orthopaedics-focused overview) and obesity pharmacotherapy. These provide mechanistic/translational context but do not establish AOD-9604 clinical outcomes [pubmed:41490200; pubmed:16931496; pubmed:17971763; pubmed:22435392; pubmed:16625817].
• Classification note: pubmed:15134286 is treated here as contextual/non-primary; it should not be used to claim human outcomes for AOD-9604 [pubmed:15134286].

Preclinical and mechanistic evidence

• Sequence/characterization: AOD-9604 corresponds to the C-terminal fragment of human growth hormone (amino acids 177–191) with an additional N-terminal tyrosine [pubmed:25208511; pubmed:11146367].
• Animal/in vitro findings (model scope reflected by titles):
• Obese mice: chronic treatment with human GH or a modified C-terminal fragment increased fat oxidation and reduced weight [pubmed:11673763].
• Obese and β3-adrenergic receptor knockout mice: human GH and the lipolytic fragment AOD-9604 affected lipid metabolism after chronic treatment [pubmed:11713213].
• In vitro/biochemical: metabolic studies of a synthetic lipolytic domain (AOD-9604) [pubmed:11146367].
• In vitro/analytical: detection and in vitro metabolism of AOD-9604 [pubmed:25208511].
• Translation caveat: Some rodent data involve fragments related to, but not necessarily identical with, AOD-9604. These results are hypothesis-generating and should not be presented as established human outcomes [pubmed:11673763; pubmed:11713213; pubmed:11146367; pubmed:25208511].

Analytical detection and anti-doping context (not clinical outcomes)

• AOD-9604 does not influence the WADA hGH isoform immunoassay; this finding is assay-specific and should not be generalized to all GH-related assays [pubmed:24124033].
• Mass-spectrometry reviews and detection/metabolism studies describe analytical identification of peptides/AOD-9604; these do not inform clinical benefit [pubmed:26213263; pubmed:25208511].

What is not established (limitations from the packet)

• Broad claims of clinical efficacy beyond the specific human endpoints studied are not supported by the provided citations in this packet [crossref:10.2165/00128413-200313770-00018; fda:pcac-aod-9604-183891; fda:pcac-aod-9604-183584].
• Dosing guidance and generalized safety outside the studied setting are not justified by the packet [fda:pcac-aod-9604-183584; crossref:10.2165/00128413-200313770-00018].
• Animal/in vitro findings should not be reframed as proven clinical efficacy; mechanistic plausibility alone does not establish clinical utility [pubmed:11673763; pubmed:11713213; pubmed:11146367; pubmed:25208511].

FAQ

• What human outcomes are supported for AOD-9604?
• In this packet, a phase II study reported favorable safety/tolerability; no human efficacy outcomes are established in the provided citations [crossref:10.2165/00128413-200313770-00018; fda:pcac-aod-9604-183891; fda:pcac-aod-9604-183584].
• Does AOD-9604 reduce fat or weight in humans?
• Not established in this packet. Rodent studies reported metabolic/weight effects, but these are not evidence of human outcomes [pubmed:11673763; pubmed:11713213].
• What exactly is AOD-9604?
• A peptide corresponding to hGH residues 177–191 with an added N-terminal tyrosine, characterized in preclinical/analytical work [pubmed:25208511; pubmed:11146367].
• Does AOD-9604 interfere with growth hormone anti-doping tests?
• One study found it does not influence the WADA hGH isoform immunoassay; this is assay-specific and does not generalize to all assays. Detection by mass spectrometry is described in analytical literature [pubmed:24124033; pubmed:26213263; pubmed:25208511].
• Are there dosing or broad safety recommendations?
• No. The packet does not justify dosing guidance or generalized safety beyond the cited human study context [fda:pcac-aod-9604-183584; crossref:10.2165/00128413-200313770-00018].

References

• [crossref:10.2165/00128413-200313770-00018] The anti-obesity drug AOD-9604* has demonstrated favourable safety and tolerability in a phase II clinical trial. https://doi.org/10.2165/00128413-200313770-00018
• [fda:pcac-aod-9604-183891] FDA PCAC meeting material: AOD-9604 clinical and regulatory context. https://www.fda.gov/media/183891/download
• [fda:pcac-aod-9604-183584] FDA PCAC support document: AOD-9604 literature and clinical-study review. https://www.fda.gov/media/183584/download
• [pubmed:41490200] Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. https://pubmed.ncbi.nlm.nih.gov/41490200/
• [pubmed:15134286] AOD-9604 Metabolic. https://pubmed.ncbi.nlm.nih.gov/15134286/
• [pubmed:25208511] Detection and in vitro metabolism of AOD9604. https://pubmed.ncbi.nlm.nih.gov/25208511/
• [pubmed:26213263] Human sports drug testing by mass spectrometry. https://pubmed.ncbi.nlm.nih.gov/26213263/
• [pubmed:11713213] The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. https://pubmed.ncbi.nlm.nih.gov/11713213/
• [pubmed:16931496] Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors. https://pubmed.ncbi.nlm.nih.gov/16931496/
• [pubmed:17971763] [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]. https://pubmed.ncbi.nlm.nih.gov/17971763/
• [pubmed:11673763] Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. https://pubmed.ncbi.nlm.nih.gov/11673763/
• [pubmed:22435392] Current updates in the medical management of obesity. https://pubmed.ncbi.nlm.nih.gov/22435392/
• [pubmed:16625817] Obesity drugs in clinical development. https://pubmed.ncbi.nlm.nih.gov/16625817/
• [pubmed:11146367] Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. https://pubmed.ncbi.nlm.nih.gov/11146367/
• [pubmed:24124033] AOD-9604 does not influence the WADA hGH isoform immunoassay. https://pubmed.ncbi.nlm.nih.gov/24124033/